Phosphodiesterase 4 (
PDE4) inhibitors are used to treat autoimmune and inflammatory diseases, such as
psoriasis and
chronic obstructive pulmonary disease (
COPD).
CHF6001 is a novel, potent and selective inhaled
PDE4 inhibitor in development for the treatment of
COPD. When tested in vitro on human dendritic cells (DCs),
CHF6001 decreased the release of pro-inflammatory
cytokines (TNF-α and IL-6),
chemokines (CXCL8, CCL3, CXCL10 and CCL19) and of Th1- and Th17-polarizing
cytokines (IL-12, IL-23 and IL-1β). In contrast to β-methasone, a reference
steroid anti-inflammatory
drug,
CHF6001 increased the secretion of CCL22, a Th2 recruiting
chemokine, and the expression of the
lymph node homing receptor CCR7. Accordingly, the migration of DCs to CCR7
ligands was increased, while migration to pro-inflammatory
chemokines was decreased. Of note, the action of
CHF6001 was apparently mediated by a promoter-specific decrease in NF-κB p65 recruitment, independent of perturbation of LPS signalling or NF-κB nuclear translocation. Our results indicate that
CHF6001 can modulate DC pro-inflammatory Th1/Th17 polarizing potential by fine tuning the transcriptional activity of the master inflammatory
transcription factor NF-κB. Therefore,
CHF6001 may prove useful to control Th1/Th17-polarized inflammatory diseases such as
COPD.